arrow
L

Lei Deng

chinese academy of medical sciences - peking union medical college
H指数:21
被引数:1,147

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term outcomes of S-1-based chemoradiotherapy in inoperable elderly patients with esophageal carcinoma: A multicenter, randomized, phase III clinical trial

S-1为基础的放化疗在不可手术的老年食管癌患者中的长期疗效:一项多中心、随机、III期临床试验

2025-12-160
PRE
Simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal squamous cell carcinoma: A multicenter, open-label, randomized, phase III clinical trial

同步整合推量调强放射治疗联合或不联合同期化疗在食管鳞状细胞癌患者中的应用:一项多中心、开放标签、随机、III期临床试验

2025-10-150
PRE
Efficacy and safety of oral vinorelbine with concurrent radiotherapy in unresectable stage III non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a single-arm, phase 2 trial

口服长春瑞滨联合同期放疗在不可切除III期非小细胞肺癌新辅助化疗免疫治疗后患者的疗效与安全性:一项单臂、II期临床试验

2025-07-210
OAAI
Impact of locoregional recurrence versus distant metastasis on overall survival in patients with Non-Small cell lung cancer after Surgery: A secondary analysis of PORT-C RCT

手术后的非小细胞肺癌患者中,局部区域复发与远处转移对总生存期的影响:PORT-C随机对照试验的二次分析

2025-01-010
PRE
Predicting muscle invasion in bladder cancer based on MRI: A comparison of radiomics, and single-task and multi-task deep learning

基于MRI预测膀胱癌的肌肉侵犯: 放射组学、单任务和多任务深度学习的比较

2023-05-0121
PRE
Applying post-neoadjuvant pathologic stage as prognostic tool in esophageal squamous cell carcinoma

新辅助后病理分期作为预后工具在食管鳞状细胞癌中的应用

2022-11-104
OAAI
Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis
2022-10-281
OAAI
Survival benefit of surgery in patients with clinical T4 esophageal cancer who achieved complete or partial response after neoadjuvant chemoradiotherapy or radiotherapy

新辅助放化疗或放疗后获得完全或部分缓解的临床T4期食管癌患者手术的生存获益

2022-07-264
OAAI